NCT01661790

Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

Open-labeled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).

Conditions

• Malignant Pleural Effusion

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
DRUG	Cisplatin	Cisplatin 30mg,intrapleural administration,each 2 week

Timeline

• Start date: 2009-08-01
• Primary completion: 2012-06-01
• Completion: 2012-10-01
• First posted: 2012-08-10
• Last updated: 2015-03-25
• Results posted: 2015-03-25

Locations

1 site across 1 country: China